Comparison table: pharmacological management of type 2 diabetes mellitus (adults)—ADA/EASD, NICE, and SIGN

Clinical guidelines are important tools for supporting decision-making, transforming best-practice, and improving patient outcomes. Where several guidelines are available for a particular clinical topic, we develop Guidelines comparison tables to allow easy access to recommendations. Collated and reviewed by our in-house pharmacists, this updated Guidelines comparison table summarises the top-line recommendations on the pharmacological management of type 2 diabetes mellitus in adults, from the following sources:

• ADA/EASD consensus report, see: Buse J, Wexler D, Tsapas A, Rossing P, Mingrone G, Mathieu C, D’Alessio D, Davies M. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020; 63(2): 221–228. Available at: link.springer.com/article/10.1007/s00125-019-05039-w
  
• NICE Guideline 28, see: NICE. Type 2 diabetes in adults: management. NICE Guideline 28. NICE; 2015 (last updated 2019). Available at: nice.org.uk/guidance/NG28
• SIGN Guideline 154, see: Scottish Intercollegiate Guidelines Network. Pharmacological management of glycaemic control in people with type 2 diabetes. SIGN Guideline 154. Edinburgh: SIGN; 2017. Available at: sign.ac.uk/sign-116-and-154-diabetes.html

The content in this Guidelines comparison table is deliberately concise and readers are strongly advised to refer to the original guidelines and consensus report as listed above. Readers should also refer to the summary of product characteristics when a drug therapy is described.